Analyst Scoreboard: 4 Ratings For Tango Therapeutics
Portfolio Pulse from Benzinga Insights
Analysts have provided diverse ratings for Tango Therapeutics (NASDAQ:TNGX) over the past three months, with a majority being bullish. The average 12-month price target has increased by 17.6% to $14.5. Tango Therapeutics is a biotechnology company focused on precision oncology therapies, showing significant revenue growth but lagging behind industry peers.
September 10, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Tango Therapeutics has received mostly bullish ratings from analysts, with an increased average price target of $14.5. The company is focused on developing precision oncology therapies and has shown significant revenue growth.
The majority of analysts have given Tango Therapeutics a bullish rating, indicating positive sentiment. The increase in the average price target suggests confidence in the company's future performance. The company's focus on precision oncology therapies and significant revenue growth further support a positive outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100